Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ

Prior treatment

• Received prior treatment or receiving current treatment for this malignancy.
• Patients who have digestive tract bleeding in 2 weeks before recruitment or with high risk of bleeding.
• Perforation / fistula of GI tract in 6 months before recruitment.
• Uncontrollable pleural effusion, pericardial effusion, or ascites in 2 weeks before recruitment.
• Patients with any cardiovascular risk factors below:
  • cardiac chest pain occurring in 28 days before recruitment, defined as moderate pain that limits daily activity.
  • pulmonary embolism with symptoms occurring in 28 days before recruitment.
  • acute myocardial infarction occurring in 6 months before recruitment.
  • any history of heart failure reaching grade 3/4 of NYHA in 6 months before recruitment.
  • ventricular arrhythmias of Grade 2 or grater in 6 months before recruitment, or accompanied by supraventricular tachyarrhythmias requiring medical treatment.
  • cerebrovascular accident within 6 months before recruitment.
• Use of steroids (dosage\>10mg/d prednisone) or other systemic immune suppressive therapy in 14 days before recruitment, except patients treated with regimens below: a. steroids for hormone replacement (dosage\>10mg/d prednisone); b. steroids for local application with little systemic absorption; c. short -term (≤ 7 days) steroids for preventing allergy or vomiting.
• Vaccinated with live vaccine in 4 weeks before recruitment.
• Receiving immune (interleukin, interferon, thymin) treatment or treatment of other trials in 28 days before recruitment.
• Receiving palliative radiation in 14 days before recruitment.
• Patients who lose ≥20% of body weight within 2 months before enrollment.
• Existing of potential situation which will impede drug administration or affect toxicity analysis or alcohol/ drug abuse.

Other illness

• Patients with upper GI tract obstruction or functional abnormality or malabsorption syndrome, which can affect absorption of apecitabine.
• Patients with active autoimmune disease or history of refractory autoimmune disease.
• Patients with active malignant tumor in recent 2 years, except the tumor studied in this research or cured locally tumor like resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ.
• Pulmonary disease history: interstitial pulmonary disease, non-infective pneumonitis, pulmonary fibrosis, acute pulmonary disease.
• Uncontrollable systemic diseases, including diabetes, hypertension, etc.
• Severe chronic or active infections in need of systemic antibacterial, antifungal, or antiviral treatment, including TB or HIV, etc.
• Patients with untreated chronic hepatitis B or HBV DNA over 500 IU/ml or positive HCV RNA.
• Allergic to any drug in this study.
• History of allogeneic stem cell transplantation or organ transplantation.
• History of anti PD-1, PD-L1, PD-L2 or any other specific T cell co-stimulation or checkpoint pathway targeted treatment.
• For patients with uncontrolled epilepsy, CNS diseases or history of mental disorder, researchers should evaluate whether their diseases will impede their signing of informed consent or compliance of treatment.

Lab values

• Moderate or severe renal injury \[creatinine clearance rate≤50 ml/min (according to Cockroft \& Gault equation)\], or Scr\>ULN.

Other

• Patients with distant metastasis or unresectable primary lesion.
• Dipyrimidine dehydrogenase (DPD) deficiency.

• Histologically or cytologically confirmed adenocarcinoma involving the gastroesophageal junction or gastric cardia.
• Having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days before enrollment.
• Being histologically diagnosed with adenocarcinoma.
• Having tumor lesions at stomach or gastroesophageal junction (Siewert type II or III);
• Clinically diagnosed stage T1-2N+M0/T3-T4aNanyM0 according to ultrasound endoscopy or enhanced CT/MRI scan.
• At least one evaluable lesion in abdominal CT/MRI according to RESIST 1.1 is required.
• Surgical consultation at enrolling site to confirm that patient will be able to undergo curative resection after completion of neoadjuvant therapy =\< 56 days prior to registration.
• Physical condition and adequate organ function to ensure the success of abdominal surgery.
• Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥90g/L.
• Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) \< 2.5 × ULN in the absence of liver metastases, or \< 5 × ULN in case of liver metastases. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.
• Adequate renal function: Serum creatinine ≤ 1.5 x ULN, and creatinine clearance ≥ 60 ml/min.
• Adequate coagulation function: INR/PT≤ 1.5 x ULN, aPTT≤ 1.5 x ULN.
• No serious concomitant disease that will threaten the survival of patients to less than 5 years.
• Male or female. Age ≥ 18 years and ≤80 years.
• Written (signed) informed consent.
• Good compliance with the study procedures, including lab and auxiliary examination and treatment.
• Female patients should not be pregnant or breast feeding.
• Female patients of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.